e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD
Lomas D. A. , Silverman E. K. , Edwards L. D. , Locantore N. W. , Miller B. E. , Horstman D. H. , Tal-Singer R. , on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators
Source:
Eur Respir J 2009; 34: 95-102
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lomas D. A. , Silverman E. K. , Edwards L. D. , Locantore N. W. , Miller B. E. , Horstman D. H. , Tal-Singer R. , on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34: 95-102
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Risk factors associated with the development of interstitial lung abnormalities
Related content which might interest you:
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013
Mechanisms of exacerbation of respiratory symptoms in patients with COPD
Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases
Year: 2006
Clinical value of C-reactive protein in severe acute exacerbations of COPD
Source: Annual Congress 2005 - COPD - acute exacerbations
Year: 2005
Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Lung function and sputum neutrophil changes in an experimental model of virus-induced COPD exacerbations
Source: Annual Congress 2005 - COPD: role of infection
Year: 2005
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Inflammatory serum profiles are consistent across independent exacerbations in COPD patients with a history of frequent exacerbations
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Source: International Congress 2016 – Inflammatory biomarkers in airway diseases
Year: 2016
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Changes in bronchial inflammation during acute exacerbations of chronic bronchitis
Source: Eur Respir J 2001; 17: 1112-1119
Year: 2001
Increased interferon and decreased NRF2-PPARG signaling is associated with frequent exacerbations in COPD
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Phenotypic markers of asthma and COPD at the tissue level
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Chronic bronchitis and plasma markers of inflammation predict incidence of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 681s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept